Emotional Blunting: Atomoxetine vs Qelbree (Viloxazine ER)
There is no published evidence directly comparing emotional blunting between atomoxetine and viloxazine ER (Qelbree), making a definitive comparison impossible based on available data.
Available Evidence on Side Effect Profiles
Atomoxetine's Documented Adverse Effects
The most common adverse effects of atomoxetine in clinical trials include 1:
- Nausea, vomiting, and gastrointestinal upset
- Fatigue and somnolence
- Decreased appetite and abdominal pain
- Headache
Importantly, emotional blunting is not listed among the documented adverse effects of atomoxetine in major pharmacological reviews or FDA labeling 1, 2. The drug has been associated with behavioral changes including suicidal ideation (particularly in children and adolescents), aggressive behavior, and mood changes, but not specifically emotional blunting 1.
Viloxazine ER's Limited Safety Data
For viloxazine ER, there is extremely limited published safety data 3, 4:
- No comprehensive adverse effect profile has been established in published guidelines
- The medication has limited data on efficacy and tolerability in adults 3
- No published studies exist regarding its use in pregnancy or breastfeeding 3
Comparative Clinical Trial Data
A 2023 head-to-head comparison study provides the only direct evidence comparing these medications 5:
- 96% of patients preferred viloxazine ER over atomoxetine
- 36% discontinued atomoxetine due to side effects (GI upset, irritability, fatigue, insomnia) versus only 4% discontinuing viloxazine ER (due to fatigue)
- Patients reported greater tolerability with viloxazine ER
- Notably, emotional blunting was not reported as a discontinuation reason for either medication 5
Clinical Interpretation
Given the absence of emotional blunting in documented adverse effect profiles for either medication, and the lack of direct comparative data on this specific outcome, neither medication appears to have a significant association with emotional blunting based on current evidence 1, 2, 5.
Key Caveats
- The superior tolerability profile of viloxazine ER in the single comparative study suggests it may have fewer subjective adverse effects overall 5
- Atomoxetine's documented side effects of fatigue and somnolence could theoretically be misinterpreted as emotional blunting 1
- The lack of emotional blunting reports may reflect underreporting rather than true absence, as this is a subjective symptom that may not be systematically assessed in clinical trials
Monitoring Recommendation
If emotional blunting is a concern, monitor for fatigue, somnolence, and irritability with atomoxetine, as these documented side effects may manifest as or contribute to perceived emotional blunting 1, 5.